Jyotivardhan Jaipuria stays overweight on banks and pharma, avoids large IT for now

Jyotivardhan Jaipuria, Founder & MD of Valentis Advisors, remains positive on banks, citing strong credit growth, improving net interest margins and attractive valuations despite recent senior management changes across private lenders. He also continues to favour pharma, particularly US generics and CDMOs, on easing pricing pressure and China-plus-one opportunities. Jaipuria stays underweight on large IT, saying acquisitions may take time to deliver, while preferring select auto ancillaries with domestic, EV, defence and aerospace exposure.